Skip to content

Karolina E. Kolaczynska

11 papers in the library · 690 citations · publishing 2018-2025

Papers

Sort Most recent Most cited

Receptor interaction profiles of 4-alkoxy-2,6-dimethoxyphenethylamines (Ψ derivatives) and related amphetamines

Frontiers in Pharmacology November 20, 2025 Karolina E. Kolaczynska, Daniel Trachsel, Marius C. Hoener et al. 1 citation

Background 4-substituted 2,6-dimethoxyphenethylamines and the corresponding amphetamines (so-called pseudo [Ψ] derivatives) are a hitherto mostly unexplored group of psychedelics. Still, preliminary investigations indicate that these derivatives are promising and potent psychedelics in humans. In this study, we examined the monoamine receptor and transporter interaction properties of several...

DOI: 10.3389/fphar.2025.1703480 (opens in new tab) Receptor Cricetulus Structure–activity relationship Hek 293 cells +7

In vitro and in vivo metabolism of psilocybin’s active metabolite psilocin

Frontiers in Pharmacology April 29, 2024 Jan Thomann, Oliver V Stoeckmann, Deborah Rudin et al. 52 citations

In vivo , psilocybin is rapidly dephosphorylated to psilocin which induces psychedelic effects by interacting with the 5-HT 2A receptor. Psilocin primarily undergoes glucuronidation or conversion to 4-hydroxyindole-3-acetic acid (4-HIAA). Herein, we investigated psilocybin’s metabolic pathways in vitro and in vivo , conducting a thorough analysis of the enzymes involved. Metabolism studies were...

DOI: 10.3389/fphar.2024.1391689 (opens in new tab) Psilocybin Metabolite Glucuronidation Cytochrome p450 +8

Pharmacokinetics and Pharmacodynamics of Oral Psilocybin Administration in Healthy Participants

Clinical Pharmacology & Therapeutics December 12, 2022 Friederike Holze, Urs Duthaler, Anna M Becker et al. 116 citations

Psilocybin is being investigated as a potential treatment for psychiatric and neurological disorders. Only a few studies have evaluated the pharmacokinetics (PKs) of psilocybin and have used body weight‐adjusted dosing. Data on PKs and the PK‐pharmacodynamic (PD) relationship of fixed doses that are commonly used are unavailable. The present study characterized the PKs and PK‐PD relationship of...

DOI: 10.1002/cpt.2821 (opens in new tab) Psilocybin Pharmacology Pharmacokinetics Pharmacodynamics +5

Pharmacological characterization of 3,4-methylenedioxyamphetamine (MDA) analogs and two amphetamine-based compounds: ,α-DEPEA and DPIA

European Neuropsychopharmacology April 1, 2022 Karolina E. Kolaczynska, Paula Ducret, Daniel Trachsel et al. 7 citations

3,4-methylenedioxyamphetamine (MDA) is a psychoactive compound chemically related to the entactogen MDMA. MDA shares some of the entactogenic effects of MDMA but also exerts stimulant effects and psychedelic properties at higher doses. Here, we examined the pharmacological properties of MDA analogs and related amphetamine-based compounds detected in street drug samples or in sport supplements....

DOI: 10.1016/j.euroneuro.2022.03.006 (opens in new tab) MDMA Serotonin Pharmacology Monoamine neurotransmitter +5

Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects

Neuropsychopharmacology February 25, 2022 Friederike Holze, Laura Ley, Felix Müller et al. 223 citations

Abstract Growing interest has been seen in using lysergic acid diethylamide (LSD) and psilocybin in psychiatric research and therapy. However, no modern studies have evaluated differences in subjective and autonomic effects of LSD and psilocybin or their similarities and dose equivalence. We used a double-blind, randomized, placebo-controlled, crossover design in 28 healthy subjects (14 women,...

Receptor Interaction Profiles of 4-Alkoxy-3,5-Dimethoxy-Phenethylamines (Mescaline Derivatives) and Related Amphetamines

Frontiers in Pharmacology February 9, 2022 Karolina E. Kolaczynska, Dino Luethi, Dino Luethi et al. 16 citations

3,4,5-Trimethoxyphenethylamine (mescaline) is a psychedelic alkaloid found in peyote cactus. Related 4-alkoxy-3,5-dimethoxy-substituted phenethylamines (scalines) and amphetamines (3C-scalines) are reported to induce similarly potent psychedelic effects and are therefore potential novel therapeutics for psychedelic-assisted therapy. Herein, several pharmacologically uninvestigated scalines and...

Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Double‐Blind, Placebo‐Controlled, Crossover Study in Healthy Subjects

Clinical Pharmacology & Therapeutics November 7, 2021 Anna M Becker, Friederike Holze, Tanja Grandinetti et al. 177 citations

The psychedelic psilocybin is being investigated for the treatment of depression and anxiety. Unclear is whether antidepressant treatments interact with psilocybin. The present study used a double‐blind, placebo‐controlled, crossover design with two experimental test sessions to investigate the response to psilocybin (25 mg) in healthy subjects after pretreatment with escitalopram or placebo....

DOI: 10.1002/cpt.2487 (opens in new tab) Psilocybin Escitalopram Placebo Crossover study +5

The Pharmacological Profile of Second Generation Pyrovalerone Cathinones and Related Cathinone Derivative

International Journal of Molecular Sciences July 31, 2021 Karolina E. Kolaczynska, Jan Thomann, Marius C. Hoener et al. 35 citations

Pyrovalerone cathinones are potent psychoactive substances that possess a pyrrolidine moiety. Pyrovalerone-type novel psychoactive substances (NPS) are continuously detected but their pharmacology and toxicology are largely unknown. We assessed several pyrovalerone and related cathinone derivatives at the human norepinephrine (NET), dopamine (DAT), and serotonin (SERT) uptake transporters using...

DOI: 10.3390/ijms22158277 (opens in new tab) Cathinone Pharmacology Potency Dopamine transporter +4

Receptor Interaction Profiles of 4-Alkoxy-Substituted 2,5-Dimethoxyphenethylamines and Related Amphetamines

Frontiers in Pharmacology November 28, 2019 Karolina E. Kolaczynska, Dino Luethi, Daniel Trachsel et al. 24 citations

Background: 2,4,5-Trimethoxyamphetamine (TMA-2) is a potent psychedelic compound. Structurally related 4-alkyloxy-substituted 2,5-dimethoxyamphetamines and phenethylamine congeners (2C-O derivatives) have been described but their pharmacology is mostly undefined. Therefore, we examined receptor binding and activation profiles of these derivatives at monoamine receptors and transporters....

DOI: 10.3389/fphar.2019.01423 (opens in new tab) Serotonin 5-HT Receptor Pharmacology Intrinsic activity +4

Metabolites of the ring-substituted stimulants MDMA, methylone and MDPV differentially affect human monoaminergic systems

Journal of Psychopharmacology April 30, 2019 Dino Luethi, Karolina E. Kolaczynska, Melanie Walter et al. 39 citations

Background: Amphetamine analogs with a 3,4-methylenedioxy ring-substitution are among the most popular illicit drugs of abuse, exerting stimulant and entactogenic effects. Enzymatic N-demethylation or opening of the 3,4-methylenedioxy ring via O-demethylenation gives rise to metabolites that may be pharmacologically active. Indeed, previous studies in rats show that specific metabolites of...

Pharmacological profile of mephedrone analogs and related new psychoactive substances.

Neuropharmacology May 15, 2018 Dino Luethi, Karolina E. Kolaczynska, Luca Docci et al.

Mephedrone is a synthetic cathinone and one of the most popular recreationally used new psychoactive substances. The aim of the present study was to characterize the in vitro pharmacology of novel analogs of mephedrone and related newly emerged designer stimulants. We determined norepinephrine, dopamine, and serotonin transporter inhibition potencies and monoamine release in...

DOI: 10.1016/j.neuropharm.2017.07.026 (opens in new tab) Full text (opens in new tab) Mephedrone Monoamine New psychoactive substances Receptors +1